China Medical System Holdings Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHSYF research report →
About the company
China Medical System Holdings Limited functions as an investment holding enterprise with a primary focus on the pharmaceutical sector within the People's Republic of China. The company's core activities involve the development, marketing, and distribution of a comprehensive range of pharmaceutical products. Its diverse portfolio addresses a wide array of medical conditions, offering treatments for cardiovascular issues (such as Plendil for hypertension and Imdur for heart disease), mental health disorders (including Deanxit for depression and anxiety), and various gastrointestinal ailments (like Ursofalk for gallstones and Salofalk for inflammatory bowel conditions).
- CEO
- Kong Lam
- IPO
- 2013
- Employees
- 6,141
- HQ
- North Point, HK
Price Chart
- Market Cap
- $3.80B
- P/E
- 16.21
- P/S
- 2.95
- P/B
- 1.39
- EV/EBITDA
- 12.19
- Div Yield
- 2.83%
- Gross Margin
- 71.50%
- Op Margin
- 19.22%
- Net Margin
- 18.13%
- ROE
- 8.65%
- ROIC
- 5.89%
- Revenue
- $8.00B · 7.11%
- Net Income
- $1.45B · -10.45%
- EPS
- $0.60 · -10.45%
- Op Income
- $1.54B
- FCF YoY
- -69.97%
- 52W High
- $1.64
- 52W Low
- $0.93
- 50D MA
- $1.38
- 200D MA
- $1.36
- Beta
- 1.08
- Avg Volume
- 4
Get TickerSpark's AI analysis on CHSYF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CHSYF coverage
Recent articles, reports, and earnings notes.
No research on CHSYF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHSYF report →Similar companies
Peers in the same neighborhood.